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telcagepant on αCGRP induced
vasorelaxation and intracellular Ca2+ levels
in the perfused and non-perfused isolated
rat middle cerebral artery
André Erdling1* , Majid Sheykhzade2 and Lars Edvinsson3
Abstract
Background: Calcitonin gene-related peptide (CGRP) is one of the most potent endogenous vasodilators identified
to date. The present study elucidates the differential interaction of CGRP, its receptor and the effect of the CGRP-
receptor antagonist telcagepant on intracellular Ca2+ -levels and tension in rat middle cerebral arteries (MCA) by
pressurized arteriography, FURA-2/wire myography and immunohistochemistry.
Methods: A pressurized arteriograph system was used to evaluate changes in MCA tension when subjected to
CGRP and/or telcagepant. Intracellular calcium levels were evaluated using a FURA-2/wire myograph system.
Localization of the CGRP-receptor components was verified using immunohistochemistry.
Results: Abluminal but not luminal αCGRP (10-12-10-6 M) caused concentration-dependent vasorelaxation in rat
MCA. Luminal telcagepant (10-6 M) failed to inhibit this relaxation, while abluminal telcagepant inhibited the
relaxation (10-6 M). Using the FURA-2 method in combination with wire myography we observed that αCGRP
reduced intracellular calcium levels and in parallel the vascular tone. Telcagepant (10-6 M) inhibited both
vasorelaxation and drop in intracellular calcium levels. Both functional components of the CGRP receptor, CLR
(calcitonin receptor-like receptor) and RAMP1 (receptor activity modifying peptide 1) were found in the smooth
muscle cells but not in the endothelial cells of the cerebral vasculature.
Conclusions: This study thus demonstrates the relaxant effect of αCGRP on rat MCA. The vasorelaxation is
associated with a simultaneous decrease in intracellular calcium levels. Telcagepant reduced relaxation and
thwarted the reduction in intracellular calcium levels localized in the vascular smooth muscle cells. In addition,
telcagepant may act as a non-competitive antagonist at concentrations greater than 10-8 M.
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Background
Calcitonin gene-related peptide (CGRP) is a 37-amino
acid neuropeptide belonging to the calcitonin family of
peptides, which also includes calcitonin, amylin and
adrenomedullin. The peptide, which was first identified
in 1982 [1], exists in two forms, αCGRP and βCGRP of
which αCGRP is more abundant in the circulation and
in the nervous system [2]. CGRP is widely distributed
throughout the central, peripheral and enteric nervous
systems [3–5] and has strong vasodilatory properties, es-
pecially in the microvasculature and in cerebral arteries
[6–8]. CGRP is commonly co-localized with substance P
in sensory neurons [9]. Cerebral αCGRP is stored in peri-
vascular sensory C-fibers that originates in the trigeminal
ganglion. The vasomotor actions of αCGRP are implied in
a variety of both physiological and pathological processes,
including migraine and other primary headaches as well
as subarachnoidal hemorrhage (SAH) [10, 11].
The CGRP receptor is a complex consisting of the G-
protein coupled calcitonin receptor-like receptor (CLR)
and a single transmembrane receptor activity modifying
protein (RAMP1) [12]. CLR may form complexes with
other RAMPs with receptor affinity modulation as a re-
sult. CLR/RAMP2 has, for instance, a high affinity for
adrenomedullin (AM) and constitutes the AM1 receptor
[13] while CLR/RAMP3 forms the AM2 receptor with re-
ported affinity for both CGRP and adrenomedullin [14].
There is also evidence of a third, intracellularly located,
receptor component protein (RCP), which is thought to
stabilize the interaction between the CLR/RAMP1-complex
and the G-proteins [15, 16]. In most tissues, receptor acti-
vation causes interaction with Gs which activates adenylate
cyclase (AC) and stimulates the generation of cyclic adeno-
sine monophosphate (cAMP) with subsequent activation of
protein kinase A (PKA) leading to opening of K+ATP- [17]
and KCa
2+ channels [18] and hyperpolarization of smooth
muscle cell membrane. A recent study demonstrates that a
major portion of CGRP induced vasodilation in MCAs is
attributed to activation of Kv7.4 channels [19]. In some vas-
cular beds, for instance in the rat aorta [6], CGRP-induced
vasodilation is to some extent mediated via release of nitric
oxide from the endothelium rather than only a direct effect
on the smooth muscle cells (SMC). The dilatory effect on
feline cerebral arteries is however clearly endothelium inde-
pendent and is associated with activation of AC [20]. The
same is true for human cerebral, meningeal and temporal
arteries [21–23].
In the present study, we have evaluated in more detail
the functional effects of high concentrations of the
CGRP-receptor antagonist telcagepant (MK-0974) on
αCGRP-induced vasodilatation in isolated middle cerebral
arteries (MCA) of rat, using (i) pressurized myography
and (ii) FURA-2-AM for measurement of intracellular
calcium performed simultaneously with recordings of
isometric tension development. We also evaluated the
distribution of the CGRP receptor components using im-
munohistochemistry. The results suggest (i) presence of
CGRP receptors on the smooth muscle cells of the MCA,
(ii) absence of CGRP receptors on the vascular endothe-
lium, (iii) coupling of receptor-ligand interaction to ten-
sion and intracellular calcium and (iv) concentration-
dependent antagonism of CGRP-induced vasodilation by
telcagepant.
Methods
The experimental protocol was reviewed and approved
by the Animal Protocol Review committee at Lund Uni-
versity, Sweden (M111-04).
Male Sprague-Dawley rats (250 – 350 g; n = 20) were
anaesthetized with CO2 and sacrificed by decapitation.
The brain was immediately removed, and placed in oxy-
genated (95% O2 and 5% CO2), cold (~ 4° C) buffer solu-
tion of the following composition: 119 mM NaCl, 15
mM NaHCO3, 4.6 mM KCl, 1.2 mM MgCl2, 1.2 mM
NaH2PO4, 1.5 mM CaCl2 and 5.5 mM glucose.
The middle cerebral artery (MCA) was carefully iso-
lated from the brain under a stereomicroscope. Each
MCA was cut into smaller segments, beginning at the
circle of Willis and extending 6-8 mm distally. The dis-
section was done in cold and oxygenated buffer solution
(see composition above).
Pressurized arteriography experiments
4–6 mm long segments of the MCA were mounted be-
tween glass micropipettes and fitted in a pressurized ar-
teriography system (Living Systems, Burlington, VT,
USA) as previously described [24]. The artery segments
were immersed in buffer solution which was kept at 37°
C and continuously aerated with a gas mixture contain-
ing 95% O2 and 5% CO2 with a pH of 7.4. Transmural
pressure and luminal perfusion was adjusted to 85
mmHg and 100 μL/min (range 70-100 μL), respectively,
by adjusting two fluid reservoirs, which were connected
to the afferent (inlet) and efferent (outlet) micropipettes
and placed at the appropriate height above the perfused
artery segment.
The setup was visualized by a microscope (at 600-fold
magnification) connected to a digital camera (Axis,
Lund, Sweden). Images recorded by the camera were
exported to and stored on a computer. Outer vessel
diameter was measured every second and evaluated in
the computer software Mary® (Nihil KB, Lund, Sweden).
Following mounting, the perfused vessels were allowed
to equilibrate and attain a stable tone. The mean diam-
eter of the vessel segments immediately after mounting
was 197.7 ± 4.6 μm and the mean diameter after gaining
tone was 132.4 ± 2.0 μm which equals contraction by
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33.0 ± 2.0%. Failure to contract at least 10% within one
hour disqualified the vessel segment from further experi-
ments. The remaining segments had ATP (10-5 M)
added to their luminal perfusate in order to evaluate
endothelial viability [25]. A dilatory response of at least
10% was considered indicative of a functional endothe-
lium and a structurally intact blood-brain barrier [24,
26]. The mean diameter of the vessel segments increased
by 36.1 ± 4.8% upon ATP exposure. The vessel segments
were once again allowed to equilibrate (i.e. attain stable
tone) before any further experiments were conducted.
Subsequently, αCGRP was added in increasing con-
centrations (10-12 to 10-6 M) to either the luminal or
the abluminal perfusate in order to evaluate the vas-
cular response.
In a separate experiment, the CGRP antagonist telca-
gepant was added to either the luminal (10-6 M) or the
abluminal perfusate (10-7-10-6 M) 30 minutes before ad-
ministration of increasing concentrations of abluminal
αCGRP.
At the end of each experiment, the vessels were treated
with calcium free buffer solution in order to elicit maximal
dilatation. The diameter increased by 30.7 ± 4.4% after
treatment with calcium free buffer.
Intracellular calcium measurements
Intracellular calcium measurements were conducted in
the dark on middle cerebral artery segments mounted in
a wire myograph placed on the stage of an inverted
microscope (Leica DMIRBE, Germany). The arteries
were loaded with the fluorescent [Ca2+]i indicator dye
(FURA-2/AM) by incubation in an oxygenated buffer so-
lution (10 μM FURA-2/AM, 0.2% (VV-1), anhydrous
dimethylsulphoxide (DMSO), 0.01% (VV-1), pluronic F-
127 and 0.03% (VV-1) cremophore EL) for 45 minutes at
37° C. Cremophore EL and pluronic F-127 (dispersing
agents or non-ionic detergents) improved the loading
with FURA-2/AM by promoting dye dispersion and
by preventing FURA-2/AM from precipitation [27].
The loading procedure was performed twice before
the vessels were washed and equilibrated for 15 mi-
nutes in buffer solution. This also allowed the FURA-
2/AM to be converted to active FURA-2 by intracel-
lular esterases.
Determination of intracellular calcium levels was per-
formed by illuminating the vessel segments with light at
340 and 380 nm, respectively. A xenon arc lamp pro-
vided high intensity continuous broadband illumination.
The emitted light was passed through filters (500 –530
nm) and detected by a photomultiplier (PTI: Photon
Technology International, Germany). During the experi-
ments, in which the vessels were precontracted with
U44619 (10-7 M) and then subjected to incremental con-
centrations of αCGRP ± telcagepant, fluorescence signals
and force signals were continuously captured and proc-
essed by a computer (FeliX32 program, Photon Technol-
ogy International, Monmouth Junction, NJ, U.S.A.). The
actual calcium concentrations were calculated according
to the equation; [Ca2+]i = Kd×β×[(R-Rmin)/(Rmax-R)],
where Kd is the dissociation constant of the FURA-2-
Ca2+ complex (224 nM at 37° C [28]), R is the measured
background-corrected ratio between emission at 340 nm
excitation and emission at 380 nm excitation, Rmax and
Rmin are background-corrected ratios under Ca
2+-satur-
ating and Ca2+-free conditions, respectively. The β is the
ratio of emission signals when excited at 380 nm during
determination of Rmin and Rmax, respectively. Rmin and
Rmax were determined in each vessel at the end of the
experiment by adding 40 μM ionomycin in calcium free
buffer solution and by using buffer-solution containing 5
mM Ca2+, respectively [29]. Before calculating the ratio
(R) between emission after 340 nm illumination and
emission after 380 nm illumination, background fluor-
escence signals were obtained by quenching the
calcium-sensitive FURA-2 fluorescence with 20 mM
Mn2+ at the end of each experiment [27, 29]. The mean
values (n = 15) of Rmin, Rmax and β were 1.12 ± 0.02,
4.59 ± 0.19 and 2.11 ± 0.18, respectively. The values
in Ca2+-free buffer and the plateau phases were desig-
nated to be 0 and 100% for both the [Ca2+]i and ten-
sion, respectively.
Immunohistochemistry
MCAs from male Sprague-Dawley rats were carefully
dissected from the brain as described above, fixed in 4%
paraformaldehyde in phosphate buffer for 1 h, followed
by rinsing in Soerensen’s phosphate buffer with increas-
ing concentrations of sucrose. The fixed specimens were
then placed into Tissue TEK (Gibo, Invitrogen A/S,
Taastrup, Denmark), frozen on dry ice and sectioned
into 10-μm-thick slices, which were rehydrated in phos-
phate buffer solution (PBS) containing 0.25% Triton X-
100 for 15 minutes before incubation overnight at +4° C
Table 1 Details of antibodies used for immunohistochemistry
Primary antibodies, Immunohistochemistry
Product ID Detects Host Dilution Supplier
RAMP1
3158
C-terminal
of rat RAMP1
Rabbit 1:200 Merck & Co. Inc, USA
CLR 132 C-terminal
of rat CRLR
Sheep 1:100 Merck & Co. Inc, USA
Secondary antibodies, Immunohistochemistry
Product ID Conjugate
and host
Dilution Supplier
10006588 FITC, goat
anti-rabbit
1:100 Cayman chemical, Ann
Arbor, MI, USA
713-516-
147
Dy594, donkey
anti-sheep
1:200 Jackson ImmunoResearch,
Europe Ltd., Suffolk, UK
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with the following primary antibodies: rabbit polyclonal
to RAMP1 diluted 1:200 and sheep polyclonal to CLR
(details for the antibodies are summarized in Table 1).
All primary antibodies were diluted in PBS containing
0.25% Triton X-100. Sections were subsequently incu-
bated for 1 hour at room temperature with secondary
FITC-conjugated donkey anti-rabbit or Dy594-conjugated
donkey anti-rabbit antibodies diluted 1:200 in PBS con-
taining 0.25% Triton X. The sections were subsequently
washed with PBS and mounted with Vectashield mount-
ing medium (Vector laboratories, Inc. Burlingame, CA,
USA). Immunoreactivity was visualized and photographed
using a light- and epifluorescence microscope (Nikon 80i;
Tokyo, Japan) at the appropriate wavelength. The same
procedure was used for the negative controls except that
the primary antibodies were omitted resulting in no stain-
ing in the tissue except for auto-fluorescence in the in-
ternal elastic lamina.
Drugs
Human α-calcitonin gene-related peptide (αCGRP)
(Sigma-Aldrich, Germany) was dissolved in 0.1% bovine
serum albumin (BSA) to form a stock solution of 10-4
M. 9,11-dideoxy-9α,11α-methanoepoxy PGF2α (U46619,
Sigma-Aldrich, Germany), a thromboxane A2 agonist,
was delivered in methyl acetate (10 mg/ml). A stock so-
lution of 10-3 M was prepared by diluting the substance
in sterile water. Telcagepant (MK-0974) was synthesized
and supplied by the Medicinal Chemistry Department
(Merck, West Point, PA, USA) and dissolved in
dimethylsulphoxide (DMSO, Sigma-Aldrich, Germany)
at a concentration of 10-2 M. All stock solutions were
stored at -20° C until utilized.
Data analysis
Relaxations are expressed as percentage of the pre-tension
or [Ca2+]i level induced by 100 nM U46619. All
concentration-response curves were analyzed by iterative
non-linear regression analysis using GraphPad Prism 6.03
(GraphPad Corp, San Diego, CA, USA). Each regression
line was fitted to a sigmoid equation: E/Emax = A[M]
nH/
(A[M]nH + EC50[M]
nH), where Emax is the maximal re-
sponse developed to the agonist, A [M] is the concentra-
tion of agonist and nH is a curve-fitting parameter, the
Hill coefficient [30]. Sensitivity to agonists is expressed as
pD2 value, where pD2 = -log (EC50 [M]), and EC50 [M] is
the molar concentration of agonist required to produce
half-maximal response. Data are expressed as mean ±
SEM (n = number of rats) unless otherwise indicated. For
experiments performed on the pressurized arteriograph,
changes in measured diameters of the vessel segments are
expressed as a percentage of the resting diameter. All con-
centrations expressed indicate the final concentration in
the luminal or abluminal compartments of the pressurized
arteriograph.
The Kruskal-Wallis test or one-way ANOVA (with
Dunn’s or Dunnett’s multiple comparison test) was used
when determining differences in Emax and pD2 between
treatment groups. P-values < 0.05 were considered sig-
nificant. NS = not significant.
Results
Pressurized arteriography
Telcagepant, luminal or abluminal, did not alter the
baseline tone in the pressurized MCAs, indicating no
CGRP tone in resting MCAs.
The administration of αCGRP caused concentration-
dependent relaxation of the MCA when given ablumin-
ally (Emax 41.4 ± 7.4%, pD2 7.73 ± 0.24, n = 12). Luminal
administration of αCGRP failed to elicit any response at
concentrations up to 10-6 M (Emax 3.1 ± 1.3%, pD2 =
7.37 ± 0.65, n= 9). Luminal telcagepant (10-6M) failed to
inhibit the vasodilatory properties of abluminally applied
αCGRP (Emax 21.85 ± 4.59%, pD2 7.75 ± 0.27, n = 5, NS
for Emax). Abluminal telcagepant reduced the dilatory re-
sponse to abluminal αCGRP significantly when given at
high concentration (10-6 M) (Emax 10.10 ± 1.84%, pD2
7.72 ± 0.30, n = 4, p = 0.014 for Emax) while lower
concentration of telcagepant (10-7 M) failed to do so (Emax
19.74 ± 11.06%, pD2 7.65 ± 0.69, n = 4, NS for Emax) (Fig. 1).
Intracellular calcium measurements
Incremental administration of αCGRP caused vasodilata-
tion and reduction of intracellular calcium levels. The
addition of 10-6 M telcagepant significantly offset both
the dilatory response and the reduction in intracellular
calcium mediated by CGRP (pD2 tension 9.63 ± 0.14 vs
8.03 ± 0.18, n = 5-6, p = 0.02; pD2 calcium 9.27 ± 0.11
vs 8.25 ± 0.09, n = 4, p = 0.03). In contrast, telcagepant
at the concentration of 10-7 M had no significant inhibi-
tory effect on αCGRP-induced responses (pD2 tension
9.63 ± 0.14 vs 8.97 ± 0.20, n = 5-6, NS; pD2 calcium
9.27 ± 0.11 vs 9.16 ± 0.14, n = 3-4, NS) (Fig. 2).
Immunohistochemistry
MCA segments were first stained with hematoxylin
(HTX) and inspected for general morphology; this re-
vealed a thin adventitia, a smooth muscle cell layer, an
internal elastic membrane and a single layer of endothe-
lial cells. Both RAMP1 and CLR immunoreactivity could
be detected within the smooth muscle cells of the MCA,
some RAMP1 was also detected within the endothelial
cells but no CLR. Thus, both components of the func-
tional CGRP receptor complex are present in SMC cyto-
plasm, but not in the endothelial cells (Fig. 3).
Erdling et al. The Journal of Headache and Pain  (2017) 18:61 Page 4 of 9
Fig. 1 Pressurized arteriography experiment demonstrating the vasodilatory properties of abluminal CGRP on rat MCA and the concentration-
dependent inhibition of this relaxation by telcagepant. Values given are means ± SEM, n = 4-12. * = p < 0,05 for CGRP vs CGRP + telcagepant 10-
6 M. Lum = luminal application of telcagepant
Fig. 2 Effect of 0,1μM and 1μM telcagepant on CGRP-induced reduction in [Ca2+]i (a) and tension (b) of rat MCAs pre-contracted with 0,1 μM
U46619. Relative tension and [Ca2+]i are given as percentages of the initial steady-state levels induced by 0,1 μM U46619. Points represent mean
values of n = 3 – 6 separate experiments and vertical bars indicate ± SEM
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Discussion
The present study has localized the two CGRP receptor
elements to the cerebrovascular smooth muscle cells
and demonstrates the functional effects of the CGRP-
receptor antagonist telcagepant on αCGRP-induced re-
duction in tension and intracellular calcium concentra-
tion in isolated rat MCA segments. We investigated in
some detail the dilatory response of αCGRP on precon-
tracted cerebral vessels and found that pre-treatment
with telcagepant causes a concentration-dependent in-
hibition of the dilatory response induced by abluminal
αCGRP. This was not seen when telcagepant was admin-
istered luminally. Telcagepant did not affect basal tone,
hence speaking against CGRP tone in the resting or pre-
contracted MCA. In addition, αCGRP failed to induce
dilation when given luminally. This, in combination with
the histological localization of the CGRP receptor com-
ponents in tunica media part of the vasculature, support
the opinion that CGRP-receptors are present only in the
cerebrovascular smooth muscle cells rather than on the
endothelium in the brain vasculature. The finding of
weak expression of RAMP1 but no CLR expression
could indicate that endothelial cells might express e.g.
amylin receptors, but this needs further analysis. The
study thus supports once again the important physio-
logical role of CGRP as neuropeptide, namely its pres-
ence in perivascular sensory nerve endings and its local
release to affect postsynaptic receptors on adjacent vas-
cular smooth muscle cells and subsequent diffusion
through the vessel into the blood stream. We also dem-
onstrated a direct correlation between αCGRP-induced
dilatory response and alterations in the intracellular cal-
cium levels. Telcagepant was for the first time shown to
inhibit the reduction in both tension and in intracellular
calcium levels at a given αCGRP concentration. However,
some results are a bit contradictory. Telcagepant failed to
shift the αCGRP concentration-response curve to the right
in the pressurized arteriography experiments. There was,
however, a reduction in CGRP-induced maximal vasodilata-
tion (Emax) when the vessels were subjected to telcagepant,
indicating non-competitive/unsurmountable antagonism.
In contrast, the wire myography accompanying the meas-
urement of intracellular calcium levels failed to show a drop
in Emax, but could demonstrate a rightward shift of the log
[CGRP]-response curve (change in potency) when sub-
jected to telcagepant. The difference between tension devel-
opment and receptor antagonism in the wire myographs
and pressurized arteriography system is interesting. The
cause for the discrepancy between results from the two
methods could be due to the presence of endothelial CGRP
receptors. This scenario seems unlikely since we failed to
detect CLR within the endothelium. Difference in vessel
diameter could be an issue, but all vessel segments had
similar lumen diameter and were taken from the same ana-
tomical location. The advantage of pressurized arteriog-
raphy lies in its mimicry of actual physiological conditions
such as shear stress on the endothelium caused by flow
through the vessel lumen and the separation of the luminal
and abluminal sides of the vessel wall. It has been demon-
strated that vessels in a wire myograph are less sensitive to
and respond differently to a variety of agonists (i.e. differ-
ence in maximum response and slope of the curve) when
compared to vessels in a pressurized system or in vivo [31,
32]. This might be due to the need for precontraction when
studying vasorelaxation in the wire myograph, but it may
also be due to misinterpretation of actual vasorelaxation as
measured in the pressure myograph and reduction of wall
tension as measured in the wire myograph model.
Fig. 3 Cross-sections of middle cerebral arteries showing CLR and RAMP1 expression in the smooth muscle cells of the MCA walls. Both receptor
antibodies revealed positive staining in the smooth muscle cell layer. A 50 μm marker is inserted. Figure 3a and d demonstrates the expression of
CLR and RAMP1 in the smooth muscle cells of the MCA walls. DAPI, a nucleus stain has been added to picture 3b and e. 3c and e are negative
controls where the fluorescence staining around the lumen is due to autofluorescence of the lamina elastica interna
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The results from the pressurized arteriography are con-
sistent with a recent study where the effect of different
concentrations of telcagepant was evaluated on human sub-
cutaneous arteries [33]. Telcagepant seemed to act as a
competitive antagonist at relatively low concentrations up
to 10-8 M but higher concentrations of telcagepant caused
a decrease in Emax and failed to further shift the agonist log
[concentration]-response curve to the right, indicating
unsurmountable antagonism. Similar findings were re-
ported when the effect of the CGRP receptor antagonist
BIBN4096BS (olcegepant) was tested on human subcutane-
ous arteries [34]. Further investigation of this phenomenon
is needed, especially since the small sample size and the ra-
ther large variability might be an issue.
CGRP and its receptor have been under scrutiny for
the last decade because of their implied role in migraine
and regulation of vasomotor tone [35]. CGRP-
containing trigeminal nerves have been shown to sur-
round the major cerebral and cortex pial arteries and
stimulation of these nerves releases CGRP which in turn
causes direct vasodilation via receptors located on the
vascular smooth muscle cells. It has also been sug-
gested that its action on second order neurons may
facilitate the transmission of pain to higher cortical
areas. There is an ongoing debate regarding whether
migraine pain originates in the perivascular nerves, in
the CNS or both [10, 36].
Several publications have implied a role for CGRP in
the development and prevention of cerebral vasospasm
following SAH. Levels of CGRP in cerebrospinal fluid
(CSF) and jugular vein blood are increased following
SAH [11, 37] as well as during migraine attacks [38].
Telcagepant and olcegepant started as promising
agents for the treatment of migraine. Incidence of liver
toxicity in chronic studies was, however, the main reason
that the projects were eventually terminated just before
entry on the market. Despite this, both agents remained
as important tools for the understanding of CGRP and
its role in cerebrovascular regulation and there are on-
going trials with other small molecules of the “gepant”
group, possibly lacking liver toxicity. Since telcagepant is
a rather large, hydrophilic substance, this feature might
impair its penetration through the blood-brain barrier into
the CNS. The neurogenic inflammation induced by sub-
stance P and CGRP may, however, aid the translocation of
telcagepant into the CNS through increased vascular per-
meability and reduced integrity of the blood-brain barrier
and thus enable interaction with CGRP receptors on the
abluminal surface of vessels as well as on perivascular
nerves and higher cortical structures.
Low penetration through the blood-brain barrier is
one explanation to why high plasma concentrations of
telcagepant are needed to treat migraine attacks while
vascular effects are seen at lower concentrations in vitro
[39]. This is somewhat supported by our study where we
compare the effect of CGRP and telcagepant in two dif-
ferent myograph systems. The pressurized arteriography
mimics the situation in vivo to a greater extent than the
wire-myograph setup where telcagepant has direct ac-
cess to both the luminal and abluminal surfaces of the
blood vessel. A previous attempt at comparing the differ-
ences in in vivo and in vitro potency of olcegepant and
telcagepant [40] reported a large difference in doses
needed for in vivo and in vitro effect. Other factors that
may explain this discrepancy between clinically effective
plasma concentrations and in vitro effects include a high
degree of binding to plasma proteins and delayed distri-
bution to the effect compartment.
CGRP acts as an agonist not only at the CGRP recep-
tor, but also on the amylin and adrenomedullin recep-
tors. A functional study on the potency of CGRP,
adrenomedullin and amylin at their corresponding re-
ceptors report 100-fold lower potency of CGRP at the
AM1 and AM2 receptors than at the CGRP receptor
[41]. CGRP effects mediated through interaction with
the AM receptors cannot be ruled out at the high con-
centrations used, but the presence of functional AM or
amylin receptors on the rat cerebral vasculature seems
limited as both of amylin and adrenomedullin only
caused weak dilatation when compared to CGRP [42].
Conclusions
This study demonstrates in detail the relaxant effect of
αCGRP on rat MCA. The vasorelaxation is for the first
time shown to be associated with a simultaneous de-
crease in intracellular calcium levels in the cerebral cir-
culation. Telcagepant thwarted the CGRP-induced
reduction in tension and intracellular calcium levels of
MCAs. When investigated in the pressurized arteriog-
raphy system, αCGRP produced relaxation only when
given abluminally. This observation, together with im-
munohistochemistry results, strongly suggests an expres-
sion of the CGRP receptor complex on the smooth
muscle cells in the media rather than on the endothe-
lium. It also implies that CGRP antagonists such as tel-
cagepant have to cross the blood-brain barrier in order
to block CGRP induced vasorelaxation in the cerebral
circulation. In addition, this study also supports earlier
findings suggesting that telcagepant may act as an un-
surmountable antagonist at concentrations greater than
10-8 M. Furthermore, parameters such as wall tension
(i.e. transmural pressure), flow, shear stress, myogenic
tone, and longitudinal stretch can be confounding fac-
tors affecting vascular responses to both agonists and
antagonists in vivo. Therefore, our results provide add-
itional evidences for exerting caution when extrapolating
the in vitro results to the in vivo situation.
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